Baxalta
Baxalta Incorporated was a biopharmaceutical company that specialized in developing, manufacturing, and commercializing therapies for orphan diseases and underserved conditions in hematology, immunology, and oncology. The company was a spin-off from Baxter International and became an independent entity on July 1, 2015.
History[edit | edit source]
Baxalta was created as a result of a corporate spin-off from Baxter International, a global healthcare company. The spin-off was aimed at focusing on the development and commercialization of biopharmaceutical products. On January 11, 2016, Shire announced that it would acquire Baxalta for $32 billion. The acquisition was completed on June 3, 2016, and Baxalta was integrated into Shire.
Products and Services[edit | edit source]
Baxalta's product portfolio included treatments for rare and chronic conditions in the following therapeutic areas:
Hematology[edit | edit source]
Baxalta developed therapies for bleeding disorders, including hemophilia. Their products included recombinant and plasma-derived therapies for the treatment of hemophilia A and B.
Immunology[edit | edit source]
The company offered treatments for primary immunodeficiency disorders and other immune system-related conditions. These included immunoglobulin therapies and other biologics.
Oncology[edit | edit source]
Baxalta's oncology division focused on developing treatments for various types of cancer, including hematologic malignancies and solid tumors. Their pipeline included both marketed products and investigational therapies.
Research and Development[edit | edit source]
Baxalta invested significantly in research and development to advance its pipeline of innovative therapies. The company collaborated with various academic institutions, research organizations, and other biopharmaceutical companies to enhance its R&D capabilities.
Corporate Structure[edit | edit source]
Baxalta was headquartered in Bannockburn, Illinois. The company operated globally, with a presence in over 100 countries. It employed approximately 16,000 people worldwide.
Acquisition by Shire[edit | edit source]
The acquisition by Shire was part of a strategic move to create a global leader in rare diseases and highly specialized conditions. The combined entity aimed to leverage Baxalta's expertise in hematology and immunology with Shire's existing portfolio and capabilities.
See Also[edit | edit source]
- Baxter International
- Shire (pharmaceutical company)
- Biopharmaceutical
- Hematology
- Immunology
- Oncology
References[edit | edit source]
External Links[edit | edit source]
 | This pharmacology-related article is a stub. You can help WikiMD by expanding it. |
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Contributors: Prab R. Tumpati, MD
